Drugs / AERAS-404
Trials 7 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 15 trials | ||||||
| Phase 1 | NCT02378207 | May 2015 → Oct 2016 | tuberculosis | Aeras | Completed | No outcome recorded |
| Phase 1 | NCT02420444 | Jan 2011 → May 2012 | tuberculosis | Aeras | Completed | No outcome recorded |
| Phase 1 | NCT02109874 | Dec 2008 → Dec 2010 | tuberculosis | Aeras | Completed | No outcome recorded |
| Phase 1 | NCT02074956 | May 2008 → Oct 2009 | tuberculosis | Aeras | Completed | No outcome recorded |
| Phase 1 | NCT02066428 | Nov 2007 → May 2009 | tuberculosis | Aeras | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT01861730 | Jul 2013 → Dec 2017 | tuberculosis | Aeras | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT02075203 | Feb 2014 → Aug 2017 | tuberculosis | Aeras | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 8 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AERAS 404 | “This study will complement one ongoing study (NCT02075203) evaluating the prevention of M. Tuberculosis infection using H4:IC31 (also known as AERAS-404).” NCT02378207 ↗7“AERAS 404 (H4:IC31) contains a fusion protein of 2 mycobacterial antigens (Ag85B and TB 10.4) formulated in IC31 adjuvant.” NCT02066428 ↗ |
| Known as | H4:IC31 | “AERAS 404 (H4:IC31) contains a fusion protein of 2 mycobacterial antigens (Ag85B and TB 10.4) formulated in IC31 adjuvant.” NCT02066428 ↗ |
| Modality | Vaccine | “novel TB vaccine candidate, H4:IC31 (AERAS-404)” PMID 28216183 ↗ Feb 2017 |
| Route | Intramuscular | “administered by intramuscular injection” NCT02074956 ↗ |